Other Pharma businesses have done or will be doing the same, much of R and D is moving other areas where the cost is 1/5 of that here in the US, so 5 times the number of projects ongoing for the same amount of money, which also means in the same terms there can be 4 failures of drugs in the same cost range. More from a previous post can be read here.
Phase 1 Clinical Trials could be possible in India by the year 2010 as well and China is also another emerging area. BD
Moving forward with its restructuring plan, GlaxoSmithKline announced to employees via email today that it would be laying off as many as 850 (6%) employees in its research and development units in the U.K. and in the U.S. Although the company has yet to determine exactly how many employees will be laid off, the cuts will be concentrated in its preclinical and early-stage drug development teams, and will include scientists as well as administrative staff.
"We have started consultation on proposals which could impact 850 roles within research and development in the U.K. and the U.S.," spokeswoman Claire Brough told the International Herald Tribune. "These changes are necessary as part of GlaxoSmithKline's longer-term strategy to ensure that we can invest in key areas of future growth and evolve our business to compete effectively in what is a rapidly changing and challenging environment for pharmaceutical companies."